A Study of TAK-755 in Adults With Acute Ischemic Stroke
This study is testing an investigational medicine called TAK-755 in adults who have had an acute ischemic stroke (AIS). An AIS happens when blood flow to part of the brain stops, often due to a blood clot. Researchers want to see how safe TAK-755 is and how well people tolerate it. They also want to learn if TAK-755 helps people with their daily activities and reduces the seriousness of their stroke symptoms compared to a placebo (an inactive substance that looks like the study drug). You may be able to join if you are between 18 and 80 years old and had stroke symptoms within 24 hours of enrolling. The main goal is to measure the percentage of participants who develop symptomatic intracranial hemorrhage (bleeding in the brain) within 120 hours of receiving the study drug. The study plans to enroll 222 participants, but its current status is unclear.
- Study design
- This interventional study plans to enroll 222 participants. It compares TAK-755 given intravenously (IV infusion) to a placebo IV infusion.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for symptomatic intracranial hemorrhage for up to 120 hours after receiving the study drug.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of TAK-755 in Adults With Acute Ischemic Stroke
At a glance
Conditions
NCT07392450
Where you'd take part
This study runs at 60 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Aberdeen Royal Infirmary
Cornhill, Aberdeen, United Kingdomstudy coordinator listed
Not yet recruiting
AES - AS - KLES Dr Prabhakar Kore Hospital and Medical Research Centre
Belagavi, Karnataka, Indiastudy coordinator listed
Not yet recruiting
AHEPA University General Hospital of Thessaloniki
Thessaloniki, Greecestudy coordinator listed
Not yet recruiting
All India Institute of Medical Sciences, New Delhi, Department of Neurology
New Delhi, Indiastudy coordinator listed
Not yet recruiting
Amrita Institute Of Medical Sciences and Research Centre
Kochi, Kerala, Indiastudy coordinator listed
Not yet recruiting
Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Raymond-Poincare
Garches, IDF, Francestudy coordinator listed
Not yet recruiting
Athens Navy Hospital
Athens, Greecestudy coordinator listed
Not yet recruiting
AZ Groeninge
Kortrijk, WVL, Belgiumstudy coordinator listed
Not yet recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Study Director · STUDY_DIRECTOR · Takeda
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Part A and B: Percentage of Participants who Develop Symptomatic Intracranial Hemorrhage (sICH) as Defined by the Heidelberg Bleeding Classification SystemUp to 120 hours of study drug administration
The Heidelberg Bleeding Classification System is used to determine whether an Intracranial Hemorrhage (ICH) is symptomatic (sICH) or asymptomatic (aICH). It uses a structured 7-step approach that integrates imaging findings with clinical deterioration. This algorithm includes anatomic description of hemorrhage, adjudication of neurological deterioration, and relatedness between ICH and clinical deterioration. Percentage of participants who develop sICH will be reported.